Analyst Samantha Semenkow of Citi maintained a Buy rating on BioAge Labs, Inc., retaining the price target of $15.00.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Samantha Semenkow’s rating is based on several promising developments surrounding BioAge Labs, Inc. The company has reported positive interim data from its Phase 1 study of BGE-102, a brain-penetrant NLRP3 inhibitor, which demonstrated a favorable safety profile and significant target engagement in healthy volunteers. The study showed dose-dependent pharmacokinetics and high brain penetration, with substantial suppression of IL-1β at higher doses.
Furthermore, BioAge Labs plans to expand its Phase 1 study to include obese participants with elevated inflammation markers, aiming to generate initial proof-of-concept data by the first half of 2026. A Phase 2a trial is also set to begin in the first half of 2026, targeting obese patients with cardiovascular risk factors. This trial will explore the effects of BGE-102 on various health indicators over a 12-week period. Additionally, positive data from a competitor’s similar drug provides a favorable outlook for BGE-102, supporting the Buy rating with an expected share price return of 62.7%.
According to TipRanks, Semenkow is an analyst with an average return of -9.2% and a 40.80% success rate. Semenkow covers the Healthcare sector, focusing on stocks such as MoonLake Immunotherapeutics, BioAge Labs, Inc., and Biohaven Ltd..